NCT03057288 (FIDECHO) is a NA clinical trial of fiducial markers placement in Esophageal Neoplasm, sponsored by Société Française d'Endoscopie Digestive.

Who is sponsoring NCT03057288?

NCT03057288 is sponsored by Société Française d'Endoscopie Digestive.

What drugs are being tested in NCT03057288?

Interventions in NCT03057288: fiducial markers placement.

What condition does NCT03057288 study?

NCT03057288 studies Esophageal Neoplasm, Rectal Neoplasms.

Is NCT03057288 still recruiting?

NCT03057288 is currently completed. Last updated 5 December 2022.

Last reviewed 2022-12-05 · How we verify

NCT03057288: FIDECHO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Study Evaluating the Feasibility of Fiducial Markers Placement for Patients With Esophageal or Rectal Cancer

Completed NA Last updated 5 December 2022

What this trial tests

NA trial testing fiducial markers placement in Esophageal Neoplasm in 40 participants. Completed in 2 September 2021.

Timeline

3 February 2017

Primary endpoint
2 September 2021

2 September 2021

Quick facts

Lead sponsor	Société Française d'Endoscopie Digestive
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	3 February 2017
Primary completion	2 September 2021
Estimated completion	2 September 2021
Sites	1 location across France

Drugs / interventions tested

fiducial markers placement

Conditions studied

Esophageal Neoplasm — all drugs for Esophageal Neoplasm →
Rectal Neoplasms — all drugs for Rectal Neoplasms →

Sponsor

Société Française d'Endoscopie Digestive — full company profile →

Who can join

18 and older, any sex, with Esophageal Neoplasm or Rectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a multicenter prospective observational study including consecutive patients with esophageal tumor or rectum with indication for radiotherapy The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance. The evaluation criteria are: * Success rate evaluation of the placement of two markers : one in the upper part of the tumor and one in the lower part. Success of the procedure will be evaluated by the endoscopist at the end of the procedure. Pictures of the markers will objectify the good placement of the markers. * Complications (early within 24 hours and late complications) such as pain, bleeding, perforation, infection, migration of the markers * The length of the procedure * The costs (procedure, hospitalization) * The clinical efficacy, by studying the decrease of the estimated target volume, the decrease of the dose delivered to the healthy tissue and the improvement of positioning of the irradiation beams by the radiotherapy technician * The presence of the markers at the end of the radiotherapy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Success rate of fiducial marker placement for treatment of esophageal or rectal cancers: a prospective multicenter study (FIDECHO study) (with video).
Camus M, Karsenti D, Levy J, Moreno M, et al · · 2025 · cited 3× · PMID 39173781 · DOI 10.1016/j.gie.2024.08.014

Verify or expand the search:

Other recruiting trials for Esophageal Neoplasm

Currently open trials in the same condition.

NCT06476678 — Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions · recruiting
NCT04075305 — The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study · recruiting
NCT00288119 — Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma · recruiting
NCT00431756 — Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus · active not recruiting
NCT06481449 — Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study · recruiting

Other Société Française d'Endoscopie Digestive trials

Trials by the same sponsor.

NCT07343869 — Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection · not yet recruiting
NCT06594718 — Endoscopic Treatment of Zenker's Diverticulum (ZENKTUN) · not yet recruiting
NCT06535490 — Antibiotic Prophylaxis for EUS-FNA of Pancreatic Cystic Lesions · not yet recruiting
NCT05431738 — Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) · NA · recruiting
NCT04251013 — Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03057288 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Société Française d'Endoscopie Digestive
Last refreshed: 5 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03057288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing